A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)

Phase 2

Completed

Conditions: Advanced Multiple Myeloma

Interventions: Drug: Filanesib, KSP (Eg5) inhibitor; intravenous
Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

Registration Number: NCT02092922

Lead Sponsor: Pfizer

Brief Summary: The AfFIRM Study is a Phase 2 study during which patients with advanced multiple myeloma will receive single-agent investigational study drug filanesib (ARRY-520). Patients will be followed to determine the effectiveness of filanesib in treating myeloma. Approximately 160 patients from North America and Europe will be enrolled in this study.

Eligible patients will have received at least two prior lines of therapy; have received prior bortezomib and lenalidomide; and have disease refractory to carfilzomib and/or pomalidomide.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 154

Inclusion Criteria

Patients with confirmed multiple myeloma whose treatment history must include all of the following:
1. Received at least 2 prior lines of therapy (induction therapy and stem cell transplant ± maintenance are to be considered a single line of therapy).
2. Received at least 2 cycles of a bortezomib-containing regimen and 2 cycles of a lenalidomide-containing regimen, unless intolerant to these agents (defined as requiring discontinuation due to toxicity).
3. Disease refractory to a carfilzomib-containing regimen and/or a pomalidomide containing regimen. Refractory is defined as either failure to achieve a minimal response (MR) or better while on therapy, or development of progressive disease (PD) while on therapy or within 60 days from last dose of therapy.
Measurable multiple myeloma disease, defined as meeting at least one of the following criteria within 14 days prior to first dose of study drug:
1. A monoclonal Ig (M-protein) concentration on serum protein electrophoresis (SPEP) of ≥ 1.0 g/dL.
2. Measurable urinary light chain secretion by quantitative analysis using urine protein electrophoresis (UPEP) of ≥ 200 mg/24 hours.
3. Involved serum free light chain (FLC) level ≥ 10 mg/dL, provided the serum FLC ratio is abnormal.
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 within 14 days prior to first dose of study drug.
Adequate hematology, hepatic and renal function laboratory values within 14 days prior to first dose of study drug.
Additional criteria exist.

Key

Exclusion Criteria

Prior treatment with filanesib (ARRY-520) or any other KSP inhibitor.
Past or current plasma cell leukemia.
Primary amyloidosis (amyloidosis associated with multiple myeloma is allowed).
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes).
Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to first dose of study drug.
Concomitant malignancies or previous malignancies (other than multiple myeloma) with less than a 2-year disease-free interval at the time of first dose of study drug. Patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or Stage 1 prostate cancer are eligible irrespective of the time of diagnosis.
Use of an investigational agent that is not expected to be cleared by the time of first dose of study drug or that has been demonstrated to have prolonged side effects. Patients must have recovered from all side effects to a Grade 0 or 1 (except alopecia and neuropathy).
Any severe concurrent disease or condition (including severe graft-versus-host disease, requirement for dialysis, symptomatic congestive heart failure [New York Heart Association Class III or IV], unstable angina pectoris, cardiac arrhythmia) which, in the judgment of the Investigator, would make the patient inappropriate for study participation.
Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or hepatitis C.
Acute active infection requiring treatment.
Additional criteria exist.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Filanesib	Filanesib, KSP (Eg5) inhibitor; intravenous	-
Filanesib	Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous	-

Primary Outcome Measures

Name	Time	Method
In patients with low Baseline alpha 1-acid glycoprotein (AAG), assess the efficacy of the study drug in terms of objective response rate.	up to 2 years

Secondary Outcome Measures

Name	Time	Method
In all patients, assess the efficacy of the study drug in terms of duration of response.	up to 2 years
In all patients, assess the efficacy of the study drug in terms of progression-free survival.	up to 2 years
In all patients, assess the efficacy of study drug in terms of overall survival.	up to 2 years
In all patients, assess the safety of the study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.	up to 2 years
In a subset of all patients, characterize the pharmacokinetics (PK) of the study drug in terms of plasma concentration-time profiles.	6 months
In patients with high Baseline AAG, assess the efficacy of the study drug in terms of objective response rate.	up to 2 years
In a subset of all patients, assess the correlation between study drug exposure and changes in corrected QT interval (QTc) in terms of changes in QTc versus time-matched study drug plasma concentrations.	6 months

Trial Locations

Locations (60): UAB Comprehensive Cancer Center
🇺🇸
Birmingham, Alabama, United States
City of Hope
🇺🇸
Duarte, California, United States
University of California, San Francisco Medical Center
🇺🇸
San Francisco, California, United States
University of Colorado
🇺🇸
Aurora, Colorado, United States
Colorado Blood Cancer Institute
🇺🇸
Denver, Colorado, United States
Yale Comprehensive Cancer Center
🇺🇸
New Haven, Connecticut, United States
Emory University, Winship Cancer Institute
🇺🇸
Atlanta, Georgia, United States
Northwestern University
🇺🇸
Chicago, Illinois, United States
Rush University Medical Center
🇺🇸
Chicago, Illinois, United States
Decatur Memorial Hospital
🇺🇸
Decatur, Illinois, United States
Scroll for more (50 remaining)
UAB Comprehensive Cancer Center
🇺🇸Birmingham, Alabama, United States